Palbociclib and Overall Survival - SHARE Metastatic ...

SHARE Metastatic Breast Cancer

6,598 members8,139 posts

Palbociclib and Overall Survival

Hazelgreen profile image
17 Replies

Published in Metastatic Breast Cancer and

Journal Scan / Research · June 30, 2022

Overall Survival With First-Line Palbociclib Plus Letrozole vs Placebo Plus Letrozole in Women With ER+/HER2− Advanced Breast Cancer

Journal of Clinical Oncology

TAKE-HOME MESSAGE

This updated overall survival (OS) analysis of the PALOMA-2 trial showed that, after a median follow-up period of 90 months, palbociclib plus letrozole resulted in a numerically, but not statistically significant, longer OS compared with letrozole alone for the first-line treatment in postmenopausal women with ER+/HER2− advanced breast cancer (ABC).

Palbociclib is the only CDK4/6 inhibitor that did not demonstrate an OS benefit in the first-line setting in patients with ER+/HER2− ABC.

– Jing Xi, MD, MPH

Written by
Hazelgreen profile image
Hazelgreen
To view profiles and participate in discussions please or .
Read more about...
17 Replies
Susan1953 profile image
Susan1953

Interesting information. I have been on the Ibrance and Letrozole combo over 5 years without progression.

Hazelgreen profile image
Hazelgreen in reply to Susan1953

There is more information in the abstract: ascopubs.org/doi/abs/10.120...

"median OS (95% CI) was 53.9 months (49.8–60.8) in the PAL+LET arm and 51.2 months (43.7 –58.9) in the PBO+LET arm (hazard ratio, 0.956 [95% CI, 0.777–1.177]; stratified 1-sided P=0.3378)"

Susan1953 profile image
Susan1953 in reply to Hazelgreen

Thanks. I am 69 and hoping to live to see my grandchildren grow up. I go to MDA from Alabama for scans and Dr. visits. Living For The Cure

Hazelgreen profile image
Hazelgreen in reply to Susan1953

Clearly, Susan, at 60 months, you are in the more successful 50% (top half of the median). I'm sure there are many women from the original study still going strong!

lambee9 profile image
lambee9 in reply to Hazelgreen

In fact, with 60 months progression-free survival, Susan is way outperforming the median 24.8 month median PFS from their drug trial. Go Susan! SO INSPIRING to hear real world evidence of these drugs working so well. There aren't great statistics available of how long women are surviving with mbc.

Tantalon7211 profile image
Tantalon7211 in reply to Susan1953

That’s wonderful to hear- how many mg of Ibrance are you on? I am just starting on anastronole(letrozole) and having severe nausea and diareahh - supposed to start Ibrance/ I hope I can do it and have success like you - Side effects hopefully subside

Susan1953 profile image
Susan1953 in reply to Tantalon7211

I am on 125 mg Ibrance since April 2017. I have minimal side effects probably from the letrozole. My hands have joint pain and by bedtime I am exhausted but I go strong all day.

TammyCross profile image
TammyCross in reply to Tantalon7211

Are you taking anastrazole or letrozole? I had an allergic reaction to letrozole, and other side effects, so onc switched me to anastrazole, which I tolerate much better.

NPmary profile image
NPmary

I beat another statistics- still here, 5 years on 7/13!

Susan1953 profile image
Susan1953 in reply to NPmary

it feels like passing that 5 years is a reason to celebrate. Congrats and lets live for the cure!

NPmary profile image
NPmary in reply to Susan1953

Thank uou. And 5 years for you too. Yeah.

Suzianna10 profile image
Suzianna10 in reply to NPmary

That’s great, keep on going

NPmary profile image
NPmary in reply to Suzianna10

Thank you

NPmary profile image
NPmary in reply to Suzianna10

Thank yo.

kokopelli2017 profile image
kokopelli2017 in reply to NPmary

congrats Mary!

almost there. 4 yrs and 8 months. letrozole only! bone mets and several lymph nodes in L side of neck. 'knock on wood'😉.

carole XO

Tolife_18 profile image
Tolife_18

Thank you very much for sharing.

In addition to OS, PFS (progression free survival) is very important. It’s not always coincide with OS. PFS in PALOMA-2 was statistically significant leading to approval, but OS reported after 90-month follow-up is not. It’s also important to note that this is a data from the follow-up of the patients enrolled years ago in the original clinical study. It’d be interesting to know the results from the real world data. I’m sure Pfizer will provide that to support the approval.

love2golfwell profile image
love2golfwell

When I was first diagnosed with MBC my original oncologist wanted to put me on Verzenio as she said that there was no survivorship data about Ibrance. Since I was moving the following month to another state I did not start on anything. When I came to Florida, my oncologist here recommended Ibrance and said there was survivorship data. I am on 125mg Ibrance with letrozole since November of 2020. So far so good. The only side effect is hair thinning and some loss and loss of eyelashes and eyebrows. I feel great otherwise. I really did not want to have the diarrhea that Verzenio can cause as I dealt with issues like that for many, many years as a teenager and young adult due to stressed induced IBS and it was not fun! I am hoping to stay on this combo for a long time, so it is great to see that Susan1953 has been on this combo for over 5 years. I would be extremely happy to do that as well!

You may also like...

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

7399/Overall-Survival-with-Palbociclib-and-Fulvestrant) indicates: \\"superior overall survival...

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

of the PALOMA-3 study showed superior overall survival (OS) outcomes with palbociclib plus...

Kisqali (ribociclib) update on Overall Survival improvement

ribociclib plus letrozole for the first-line therapy of HR–positive, HER2–negative advanced breast...

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

2–negative (HR+/HER2−) metastatic breast cancer (MBC) treated with first-line palbociclib plus an...

Rising ESR1 Mutations During Aromatase Inhibitor and Palbociclib Therapy

treatment with first-line aromatase inhibitors and palbociclib or switch to fulvestrant and...